CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 87 enrolled
Drug / intervention
dexamethasone intravitreal implant 0.7 mgdrug
Likely dose
dexamethasone intravitreal implant 0.7 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01445626
NCT01445626N/ACompleted
CompareCT.gov

A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)

Allergan·observational·Posted Oct 4, 2011·Updated Feb 18, 2013

In Brief

An observational study evaluating dexamethasone intravitreal implant 0.7 mg for Macular Edema. Completed, enrolled 87 participants across 1 site.

Detailed Summary

This study will use retrospective data to evaluate the efficacy, safety, and re-injection interval of OZURDEX® in the treatment of macular oedema due to Retinal Vein Occlusion (RVO).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Edema
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 4, 2011
Enrollment StartOct 1, 2011
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 14.7 years ago

Interventions

dexamethasone intravitreal implant 0.7 mgdrug

Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.